Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04605159
Registration number
NCT04605159
Ethics application status
Date submitted
22/10/2020
Date registered
27/10/2020
Date last updated
12/02/2024
Titles & IDs
Public title
A Phase III Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers
Query!
Scientific title
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Query!
Secondary ID [1]
0
0
2020-001355-40
Query!
Secondary ID [2]
0
0
212171
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
GRACE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Infections
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - RSV MAT
Treatment: Drugs - Placebo
Experimental: RSV_MAT Group - Maternal participants randomized to the RSV_MAT Group will receive a single dose of RSV MAT vaccine at day 1, via the intramuscular route; the preferred injection site will be the deltoid region of the non-dominant arm.
Placebo Comparator: Control Group - Maternal participants randomized to the Control Group will receive a single dose of Placebo at day 1, via the intramuscular route; the preferred injection site will be the deltoid region of the non-dominant arm.
Other interventions: RSV MAT
One dose of RSV MAT vaccine reconstituted with NaCl solution administered intramuscularly in the non-dominant arm.
Treatment: Drugs: Placebo
One dose of lyophilized sucrose reconstituted with NaCl solution administered intramuscularly in the non-dominant arm.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of infant participants with medically assessed, RSV-associated LRTIs, up to 6 months of age
Query!
Assessment method [1]
0
0
The vaccine arm will be compared to the placebo arm through the occurrence of severe and/or any medically assessed, RSV-associated LRTIs.
Query!
Timepoint [1]
0
0
From birth to Day 181 post birth
Query!
Primary outcome [2]
0
0
Number of infant participants with at least one SAE, AE leading to study termination or Medically Attended AE (MAE), from birth up to 6 months after birth
Query!
Assessment method [2]
0
0
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant.
A MAE is an unsolicited AE such as a symptom or illness which requires a hospitalisation, or emergency room visit, or visit to/by a health care provider.
Query!
Timepoint [2]
0
0
From birth to Month 6 post birth
Query!
Primary outcome [3]
0
0
Number of infant participants with at least one SAE, AE leading to study termination or MAE, from birth up to 12 months after birth
Query!
Assessment method [3]
0
0
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant.
A MAE is an unsolicited AE such as a symptom or illness which requires a hospitalisation, or emergency room visit, or visit to/by a health care provider.
Query!
Timepoint [3]
0
0
From birth to Month 12 post birth
Query!
Secondary outcome [1]
0
0
Number of infant participants with RSV-associated hospitalizations
Query!
Assessment method [1]
0
0
The vaccine arm will be compared to the placebo arm through the occurrence of RSV associated hospitalizations.
Query!
Timepoint [1]
0
0
From birth to Day 181 post birth
Query!
Secondary outcome [2]
0
0
Number of infant participants with all-cause LRTIs
Query!
Assessment method [2]
0
0
The vaccine arm will be compared to the placebo arm through the occurrence of all-cause LRTIs.
Query!
Timepoint [2]
0
0
From birth to Day 181 post birth
Query!
Secondary outcome [3]
0
0
Number of infant participants with all-cause LRTIs with hospitalization
Query!
Assessment method [3]
0
0
The vaccine arm will be compared to the placebo arm through the occurrence of all-cause LRTIs with hospitalization.
Query!
Timepoint [3]
0
0
From birth to Day 181 post birth
Query!
Secondary outcome [4]
0
0
Number of infant participants with medically assessed, RSV-associated severe LRTIs, up to 12 months of age
Query!
Assessment method [4]
0
0
The vaccine arm will be compared to the placebo arm through the occurrence of medically assessed, RSV-associated severe LRTIs.
Query!
Timepoint [4]
0
0
From birth to Day 366 post birth
Query!
Secondary outcome [5]
0
0
Number of infant participants with any medically assessed, RSV-associated LRTIs, up to 12 months of age
Query!
Assessment method [5]
0
0
The vaccine arm will be compared to the placebo arm through the occurrence of any medically assessed, RSV-associated LRTIs.
Query!
Timepoint [5]
0
0
From birth to Day 366 post birth
Query!
Secondary outcome [6]
0
0
Number of infant participants with severe medically assessed, RSV-associated LRTIs for RSV subtype A and RSV subtype B separately, up to 6 months of age
Query!
Assessment method [6]
0
0
The vaccine arm will be compared to the placebo arm through the occurrence of severe medically assessed, RSV-associated LRTIs for RSV subtype A and RSV subtype B separately.
Query!
Timepoint [6]
0
0
From birth to Day 181 post birth
Query!
Secondary outcome [7]
0
0
Number of infant participants with any medically assessed, RSV-associated LRTIs for RSV subtype A and RSV subtype B separately, up to 6 months of age
Query!
Assessment method [7]
0
0
The vaccine arm will be compared to the placebo arm through the occurrence of any medically assessed, RSV-associated LRTIs for RSV subtype A and RSV subtype B separately.
Query!
Timepoint [7]
0
0
From birth to Day 181 post birth
Query!
Secondary outcome [8]
0
0
Number of infant participants with medically assessed, RSV-associated LRTIs, up to 4 months of age
Query!
Assessment method [8]
0
0
The vaccine arm will be compared to the placebo arm through the occurrence of severe and any medically assessed, RSV-associated LRTIs.
Query!
Timepoint [8]
0
0
From birth to Day 121 post birth
Query!
Secondary outcome [9]
0
0
Number of infant participants with all-cause pneumonia
Query!
Assessment method [9]
0
0
The vaccine arm will be compared to the placebo arm through the occurrence of all-cause pneumonia.
Query!
Timepoint [9]
0
0
From birth to Day 181 post birth
Query!
Secondary outcome [10]
0
0
Number of infant participants with RSV-associated hospitalizations
Query!
Assessment method [10]
0
0
The vaccine arm will be compared to the placebo arm through the occurrence of RSV associated hospitalizations.
Query!
Timepoint [10]
0
0
From birth to Day 366 post birth
Query!
Secondary outcome [11]
0
0
Number of maternal participants with RSV-associated Medically Attended RTIs (RSV-MA-RTIs)
Query!
Assessment method [11]
0
0
The vaccine arm will be compared to the placebo arm through the occurrence of RSV-associated MA-RTIs.
Query!
Timepoint [11]
0
0
From Day 1 (vaccination) to Day 181 post delivery
Query!
Secondary outcome [12]
0
0
Humoral immune response in terms of RSV-A neutralizing antibody Geometric Mean Titers (GMTs) in maternal participants, at specified timepoints
Query!
Assessment method [12]
0
0
Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay.
Query!
Timepoint [12]
0
0
At Day 1 (pre vaccination), Day 31 and at Delivery
Query!
Secondary outcome [13]
0
0
Humoral immune response in terms of RSV-A neutralizing antibody GMTs in infant participants, at specified timepoints.
Query!
Assessment method [13]
0
0
Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay.
Query!
Timepoint [13]
0
0
At birth, Day 43 post birth, Day 121 post birth and Day 181 post birth
Query!
Secondary outcome [14]
0
0
Geometric mean ratio between cord blood and maternal RSV MAT IgG-specific antibody concentrations
Query!
Assessment method [14]
0
0
Transfer of RSV-specific antibodies from maternal participants vaccinated with RSV Mat to their infants is calculated as the ratio between cord blood* and maternal RSV MAT IgG-specific antibody concentrations. * or an infant blood sample collected within 72 hours after birth (if no cord blood sample can be obtained)
Query!
Timepoint [14]
0
0
At delivery or birth
Query!
Secondary outcome [15]
0
0
Number of maternal participants with solicited adverse events (AEs)
Query!
Assessment method [15]
0
0
Assessed solicited administration site events include pain, redness and swelling, at the injection site. Assessed solicited systemic events include fatigue, fever, nausea, vomiting, diarrhoea, abdominal pain and headache.
Query!
Timepoint [15]
0
0
From Day 1 to Day 7
Query!
Secondary outcome [16]
0
0
Number of maternal participants with unsolicited AEs
Query!
Assessment method [16]
0
0
Any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE.
Query!
Timepoint [16]
0
0
From Day 1 to Day 30
Query!
Secondary outcome [17]
0
0
Number of maternal participants with at least one serious adverse event (SAE), AE leading to study termination or medically attended respiratory tract illness (MA-RTI)
Query!
Assessment method [17]
0
0
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant. MA-RTI occurs when the maternal participant visits a healthcare professional (e.g., a General Practitioner) for any respiratory symptom, including (but not limited to) cough, sore throat, sputum production and difficulty breathing.
Query!
Timepoint [17]
0
0
From Day 1 (vaccination) to Month 6 post delivery
Query!
Secondary outcome [18]
0
0
Number of maternal participants with at least one other medically attended AE
Query!
Assessment method [18]
0
0
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Query!
Timepoint [18]
0
0
From Day 1 (vaccination) to Day 43 post delivery
Query!
Secondary outcome [19]
0
0
Number of maternal participants with each pregnancy outcome
Query!
Assessment method [19]
0
0
These pregnancy outcomes include live birth with no congenital anomalies, live birth with minor congenital anomaly(ies) only; live birth with at least one major congenital anomaly, fetal death/still birth (antepartum or intrapartum) with no congenital anomalies, fetal death/still birth (antepartum or intrapartum) with only minor congenital anomalies, fetal death/still birth (antepartum or intrapartum) with at least 1 major congenital anomaly; elective/therapeutic termination with no congenital anomalies; elective/therapeutic termination with only minor congenital anomalies, and elective/therapeutic termination with at least 1 major congenital anomaly.
Query!
Timepoint [19]
0
0
From Day 1 to Day 43 post delivery
Query!
Secondary outcome [20]
0
0
Number of maternal participants with each pregnancy-related AE of special interest (AESI)
Query!
Assessment method [20]
0
0
These pregnancy-related AESIs include maternal death, hypertensive disorders of pregnancy, fetal growth restriction, pathways to preterm birth, gestational diabetes mellitus and chorioamnionitis.
Worsening, post study vaccine administration, of pre-existing conditions already present at the time of enrolment. (e.g. controlled gestational hypertension or controlled gestational diabetes) are collected as (S)AEs and indicated as "worsening" or "aggravated". These are not to be considered as AESIs.
Query!
Timepoint [20]
0
0
From Day 1 (vaccination) to Day 43 post delivery
Query!
Secondary outcome [21]
0
0
Number of infant participants with each neonatal AESI
Query!
Assessment method [21]
0
0
Neonatal AESIs include small for gestational age, low birth weight including very low and extremely low birth weight, congenital anomalies, neonatal death, preterm birth.
Query!
Timepoint [21]
0
0
From birth to Day 43 post birth
Query!
Eligibility
Key inclusion criteria
Maternal participants
- Participants who, in the opinion of the investigator, can and will comply with the
requirements of the protocol.
- Participants who give written or witnessed/thumb printed informed consent after the
study has been explained, and before any study specific procedures are performed, as
per local regulations regulatory requirements.
- Age 18 to 49 years, inclusive, at the time of study intervention.
- Pre-pregnancy BMI 17.0 to 39.9 kg/m2, inclusive.
- In good general maternal health as established by medical history and clinical
examination before entering into the study.
- Singleton pregnancy (including instances where the singleton pregnancy derives from a
vanishing twin syndrome).
- At 24^0/7 to 34^0/7 weeks of gestation at the time of study vaccination (Visit 1), as
established by:
- last menstrual period (LMP) date corroborated by first or second trimester ultrasound
examination (U/S) i.e. at or before 28 weeks of gestation.
- 1st or 2nd trimester U/S only, if LMP is unknown/uncertain
- Certain LMP, corroborated by an U/S performed after 28 weeks of gestation is also
acceptable.
- No fetal genetic abnormalities (based on genetic testing, if performed).
- No significant congenital malformations, as assessed by fetal anomaly ultrasound scan
conducted at or beyond 18 weeks of gestation.
- Willing to provide cord blood.
- Who do not plan to give their child for adoption.
- Who plan to reside in the study area for at least one year after delivery.
- Willing to have the infant followed-up after delivery for a period of 12 months.
Infant participants
- Live-born from the study pregnancy.
- If required per local regulations/guidelines, re-signed (confirmed) written or
witnessed/thumb printed informed consent for study participation of the infant
obtained from the infant's mother and/or father and/or LAR, before performing any
study specific procedure. OR, if permitted by local regulation, documented verbal
consent for infant's participation obtained from the parent(s)/LAR(s) at birth,
followed by written consent obtained by (or before) Visit 2-newborn.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
49
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Maternal participants Medical conditions
- History of allergic disease or reactions likely to be exacerbated by any component of
the RSV vaccine
- Hypersensitivity to latex
- Significant complications in the current pregnancy:
- Gestational hypertension unless blood pressure it is controlled and maintained in the
normal range (<140mmHg and <90mmHg) through diet and/or antihypertensive medications
- Gestational diabetes not controlled by medication, diet and/or exercise
- Pre-eclampsia
- Eclampsia
- Intrauterine Growth Restriction/Fetal Growth Restriction
- Placenta previa
- Placental abruption, placenta accreta/percreta/increta, chorioamnionitis or any
abnormalities that can impair the maternal-fetal circulation
- Polyhydramnios
- Oligohydramnios
- Preterm labour or history of preterm labour in the current pregnancy
- Any intervention to prevent preterm delivery or medical treatment for suspected
preterm delivery, including administration of systemic corticosteroids for fetal lung
maturation
- Cholestasis
- Other pregnancy-related complications (per investigator's judgement)
- Significant structural abnormalities of the uterus or cervix
- History of 2 or more prior stillbirths or neonatal deaths/history of 2 or more preterm
births at =34 weeks gestation/3 or more consecutive spontaneous abortions
- Known HIV infection (as per serological tests performed during the current pregnancy)
- Known or suspected HBV or HCV infection
- Known or suspected infection during the current pregnancy with Toxoplasma, Parvovirus
B19, Syphilis, Zika, Rubella, Varicella, CMV or primary genital Herpes Simplex
- Active infection with tuberculosis
- Known or suspected impairment of the immune system
- Current autoimmune disorder for which the participant has received immune-modifying
therapy within 6 months before study vaccination, or plans administration through
delivery
- Lymphoproliferative disorder or malignancy within 5 years before study vaccination
- Acute or chronic clinically significant abnormality or poorly controlled pre-existent
co-morbidities or any other clinical conditions that might pose additional risk to the
participant due to participation in the study
- Any conditions that may interfere with participant's ability to comply with study
procedures or receipt of prenatal care
- Any condition which would increase the risks of study participation to the unborn
infant
Prior/Concomitant therapy
- Prior receipt of an RSV vaccine in the current pregnancy
- Use of any investigational/non-registered product other than the study vaccine/product
as described below, or planned use during the period :
- For a drug, vaccine or medical device: from 29 days before the dose of study vaccine
- For immunoglobulins: 3 months before the dose of study vaccine/product.
The exception to this is investigational products administered in the setting of a pandemic
which may be allowed following delivery
- Planned administration/administration of any vaccine from 29 days before the dose of
study vaccine or planned administration through delivery, except:
- Seasonal influenza vaccines, tetanus vaccines, dTpa/Tdap - alone vaccines, dTpa/Tdap
vaccines that also contain other antigens, Hepatitis B vaccines, and COVID-19 vaccines
all of which may be administered according to standard of care =15 days before or
after study vaccination
- Administration of immunoglobulins (except anti-Rh0D IG, which may be administered at
any time), blood products or plasma derivatives within 3 months before study
vaccination or planned administration through delivery
- Administration of immune-modifying therapy within 6 months before the study
vaccination, or planned administration through delivery. This includes but is not
limited to:
- Azathioprine, mycophenolate mofetil, 6-mercaptopurine, cyclosporine, tacrolimus,
monoclonal or polyclonal antibodies
- Prednisone =5 mg/day or equivalent for =14 days; Inhaled, intra-articular/intra-bursal
and topical steroids are allowed
- Corticosteroids administered for fetal lung maturation
Prior/Concurrent clinical study experience
- Concurrently participating in another clinical study, in which the participant has been
or will be exposed to an investigational or a non-investigational vaccine/product
Other exclusions
- Alcoholism or substance use disorder within the past 24 months based on DSM-5 criteria
- A local condition that precludes injection of the study vaccine/product or precludes
assessment of local reactogenicity
- Consanguinity of maternal participant and her partner (second degree cousins or
closer)
- Any study personnel or their immediate dependants, family or household members
Infant participants
- Concurrently participating in another clinical study, in which the participant has
been or will be exposed to an investigational or a non-investigational vaccine/product
- Any condition which would increase the risks of study participation to the infant
- Child in care.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/11/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
11/09/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
10578
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - South Brisbane
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Southport
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Geelong
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Melbourne
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [2]
0
0
4215 - Southport
Query!
Recruitment postcode(s) [3]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [4]
0
0
3168 - Melbourne
Query!
Recruitment postcode(s) [5]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Idaho
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Louisiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Michigan
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Montana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Nebraska
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Mexico
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
South Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Buenos Aires
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Tucumán
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Rio Cuarto
Query!
Country [18]
0
0
Bangladesh
Query!
State/province [18]
0
0
Dhaka
Query!
Country [19]
0
0
Bangladesh
Query!
State/province [19]
0
0
Sylhet
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Genk
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Gent
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Kortrijk
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Leuven
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Sint-Niklaas
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Rio Grande Do Sul
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
São Paulo
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Alto Da Posse, Nova Iguacu
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
São José do Rio Preto
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Nova Scotia
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Ontario
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Québec
Query!
Country [32]
0
0
Colombia
Query!
State/province [32]
0
0
Barranquilla
Query!
Country [33]
0
0
Colombia
Query!
State/province [33]
0
0
Bogota
Query!
Country [34]
0
0
Colombia
Query!
State/province [34]
0
0
Cali
Query!
Country [35]
0
0
Colombia
Query!
State/province [35]
0
0
Chía
Query!
Country [36]
0
0
Colombia
Query!
State/province [36]
0
0
Medellin
Query!
Country [37]
0
0
Dominican Republic
Query!
State/province [37]
0
0
Santo Domingo Este
Query!
Country [38]
0
0
Finland
Query!
State/province [38]
0
0
Helsinki
Query!
Country [39]
0
0
Finland
Query!
State/province [39]
0
0
Kokkola
Query!
Country [40]
0
0
Finland
Query!
State/province [40]
0
0
Oulu
Query!
Country [41]
0
0
Finland
Query!
State/province [41]
0
0
Tampere
Query!
Country [42]
0
0
Finland
Query!
State/province [42]
0
0
Turku
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Bordeaux
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Clermont Ferrand
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Montpellier cedex 5
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Paris
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Pierre Bénite
Query!
Country [48]
0
0
Honduras
Query!
State/province [48]
0
0
Comayagua
Query!
Country [49]
0
0
Honduras
Query!
State/province [49]
0
0
San Pedro Sula
Query!
Country [50]
0
0
India
Query!
State/province [50]
0
0
Kolkata
Query!
Country [51]
0
0
India
Query!
State/province [51]
0
0
Mangalore
Query!
Country [52]
0
0
India
Query!
State/province [52]
0
0
Mysuru
Query!
Country [53]
0
0
India
Query!
State/province [53]
0
0
Nagpur
Query!
Country [54]
0
0
India
Query!
State/province [54]
0
0
Pune
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Lombardia
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Piemonte
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Puglia
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Sicilia
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Toscana
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Verona
Query!
Country [61]
0
0
Korea, Republic of
Query!
State/province [61]
0
0
Daegu-si
Query!
Country [62]
0
0
Korea, Republic of
Query!
State/province [62]
0
0
Seoul
Query!
Country [63]
0
0
Mexico
Query!
State/province [63]
0
0
Michoacán
Query!
Country [64]
0
0
Mexico
Query!
State/province [64]
0
0
Nuevo León
Query!
Country [65]
0
0
Mexico
Query!
State/province [65]
0
0
Querétaro
Query!
Country [66]
0
0
Mexico
Query!
State/province [66]
0
0
Chihuahua
Query!
Country [67]
0
0
Mexico
Query!
State/province [67]
0
0
Oaxaca
Query!
Country [68]
0
0
Mexico
Query!
State/province [68]
0
0
San Luis Potosí
Query!
Country [69]
0
0
New Zealand
Query!
State/province [69]
0
0
Auckland
Query!
Country [70]
0
0
New Zealand
Query!
State/province [70]
0
0
Newtown
Query!
Country [71]
0
0
Panama
Query!
State/province [71]
0
0
Panama City
Query!
Country [72]
0
0
Panama
Query!
State/province [72]
0
0
Panama
Query!
Country [73]
0
0
Philippines
Query!
State/province [73]
0
0
Dasmariñas, Cavite
Query!
Country [74]
0
0
Philippines
Query!
State/province [74]
0
0
Manila
Query!
Country [75]
0
0
South Africa
Query!
State/province [75]
0
0
Gauteng
Query!
Country [76]
0
0
South Africa
Query!
State/province [76]
0
0
Johannesburg
Query!
Country [77]
0
0
South Africa
Query!
State/province [77]
0
0
Soshanguve
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Andalucia
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Galicia
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Madrid
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Aravaca
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Barcelona
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Basurto/Bilbao
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Burgos
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Gandía (Valencia)
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Getafe/Madrid
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Majadahonda (Madrid)
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Malaga
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Marbella
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Sevilla
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Torrejón Ardoz
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Valencia
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Valladolid
Query!
Country [94]
0
0
Taiwan
Query!
State/province [94]
0
0
Changhua
Query!
Country [95]
0
0
Taiwan
Query!
State/province [95]
0
0
Kaohsiung City
Query!
Country [96]
0
0
Taiwan
Query!
State/province [96]
0
0
Taichung
Query!
Country [97]
0
0
Taiwan
Query!
State/province [97]
0
0
Taipei City
Query!
Country [98]
0
0
Taiwan
Query!
State/province [98]
0
0
Taipei
Query!
Country [99]
0
0
Taiwan
Query!
State/province [99]
0
0
Taoyuan
Query!
Country [100]
0
0
Thailand
Query!
State/province [100]
0
0
Bangkok
Query!
Country [101]
0
0
Thailand
Query!
State/province [101]
0
0
Muang
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Edinburgh
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the ability of a single dose of the investigational
RSV Maternal vaccine, administered intramuscularly (IM) to pregnant women aged 18-49 years,
in good general maternal health, in preventing medically assessed RSV associated Lower
Respiratory Tract Illnesses (LRTIs) in infants born to vaccinated mothers. The study will
also evaluate the safety of the investigational RSV Maternal vaccine both in vaccinated
mothers and in their corresponding infant.
Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV
MAT 009), GSK made the decision to stop enrolment and vaccination in the study. Ongoing study
participants will continue to be monitored as part of the study.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04605159
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04605159
Download to PDF